Singapore markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
62.61-1.75 (-2.72%)
At close: 04:00PM EST
60.41 -2.20 (-3.51%)
Pre-market: 05:40AM EST
Full screen
Trade prices are not sourced from all markets
Previous close64.36
Open63.72
Bid0.00 x 900
Ask0.00 x 800
Day's range62.21 - 66.38
52-week range62.21 - 191.10
Volume2,213,096
Avg. volume1,545,953
Market cap4.791B
Beta (5Y monthly)2.05
PE ratio (TTM)11.90
EPS (TTM)5.26
Earnings date14 Feb 2022 - 18 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est149.11
  • Motley Fool

    Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?

    In this Motley Fool Live video recorded on Jan. 12, 2022, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the two companies are rising stars in healthcare. Keith Speights: Illumina, which we've talked about, and Beam Therapeutics, she says, "Are they rising stars, and what about other CRISPR stocks?" Are Illumina and Beam rising stars, Brian?

  • Zacks

    4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

    New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

  • Zacks

    Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

    Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.